VANCOUVER, BC, April 10, 2023 /CNW/ – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common…

Source

Previous articleCOMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference
Next articlePT404 – Clusterbusters: The Horrors of Cluster Headaches and the Miracle of Psilocybin